On May 10, 2021, the U.S. FDA authorized the Pfizer pediatric vaccine for children 12 to 15 years old under an Emergency Use Authorization (EUA), meaning the vaccine was proven safe and effective for this age group. The vaccine has since received full FDA approval. The vaccine is the same dosage and formula as the vaccine approved for adults 16 and older. Each dose is 30 mcg. In the FDA analysis, the immune response of the children to the vaccine was comparable to the immune response of the adults.
This vaccine is a two-dose series, and the doses should be administered three to eight weeks apart. An 8-week interval between the first and second doses may be best for some people age 12 and older, especially for males ages 12 to 39. Learn more here or talk with your healthcare provider. See the U.S. FDA fact sheet for more information.
The CDC recommends people 5 and older receive an age-appropriate, updated mRNA booster dose if at least 2 months have passed since their primary series or since their most recent booster dose. The updated Pfizer-BioNTech booster for people is available for people 5 and older, and the updated Moderna booster is available for people 6 and older. Pfizer’s bivalent booster for children 5 to 11 years is 10 mcg, one third of the adult bivalent booster dosage. Moderna’s bivalent booster for children 6 to 11 years is 25 mcg, one half of the adult bivalent booster dosage.